Scholarship with Impact.
Ketamine offers a promising new option for the treatment of depression, but its increasing off-label use is ethically and clinically inappropriate at the moment.
The Scattergood Program for Applied Ethics of Behavioral Health Care
Department of Medical Ethics & Health Policy
Perelman School of Medicine at the University of Pennsylvania
Blockley Hall, 14th Floor
423 Guardian Drive
Philadelphia, PA 19104-4884
Tel. (215) 898-7136
Fax (215) 573-3036